News & Analysis on Clinical Trial Services & Contract Research And Development
J&J has expressed its concern over patient safety as Novartis' subsidiary Sandoz has received the green light from the European Commission to launch the first epoetin alfa biosimilar on the EU market.
A contract research organisation (CRO) is offering a unique toxicity screening service using zebrafish as a model for assessing drug effects on cardiac function.
Bristol-Myers Squibb (BMS) has signed a license contract to use Dow Wolff Cellulosics' Foam Granulation Technology (FGT) to manufacture tablets.
The end of the tunnel seems to be getting closer for South African manufacturer Enaleni as the firm confirmed it will resume production in its recently closed Durban facility in the next ten days.
Serenex is turning the world of drug discovery inside out by first finding an effective drug candidate and then working out what its target is.
Abbott and AstraZeneca are the latest pharmaceutical companies to take on the $21.6bn (€15.8bn) cholesterol market with a combination drug.
Are profits for clinical investigative sites reduced by the presence of a contract research organisation (CRO)?
US researchers have shown certain organic solvents can be used to selectively extract therapeutic proteins from host bacteria, avoiding the need for cell lysis and increasing product purity by a factor of five.
Acambis has had its smallpox vaccine approved by the US, coming one step closer to closing another supply contract for the US Strategic National Stockpile.
Millipore has released a new kit that allows researchers to quickly generate arthritis mouse models for screening and evaluating anti-inflammatory therapeutics.